Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

317

425 Understanding Reliability of a Scarce Resource Allocation Policy: Assessing Agreement of Intensive Care Unit (ICU)

411 Using Telehealth Strategies to Increase Shared Decision Making for Lung Cancer Screening: A Pilot Randomized Controlled Trial/ K. Rendle, Philadelphia, PA 412 Lung Cancer Screening to Detect and Treat Undiagnosed Cardiovascular Disease and Chronic Obstructive Pulmonary Disease. An Analysis of the Canadian McGill Lung Cancer Screening Pilot Program Cohort/ C. Besson, Montréal, Canada 413 The Impact of Comorbidities on Lung Cancer Screening Shared Decision-making/ M.S. Kale, New York, NY 414 Chronic Breathlessness Management in Primary Care: Current Gaps and Practical Solutions/ A.P. Sunjaya, Sydney, Australia 415 An Assessment of Pressurized Metered-dose Inhaler Use in Countries in Europe and the Rest of the World/ J.P. Bell, Baar, Switzerland 416 Challenging Health Disparities in Sleep Medicine: Partnering With Community Organizations to Create a Comprehensive Sleep Clinic for Low-resource Individuals/ E. Gusman, Chicago, IL 417 Validation of Predictive Tools for Obstructive Sleep Apnea Among Pregnant Women With Overweight and Obesity/ S. Petrillo, Providence, RI 418 Use of a Behavior Change Model to Understand CPAP Usage at One Year/ L. Kaye, San Diego, CA 419 Correlation of Therapeutic Pressure Between Home Automatic Positive Airway Pressure and In-laboratory Polysomnography Manual Titration in Patients With Obstructive Sleep Apnea/ N. Saiphoklang, PathumThani, Thailand 420 Healthy Brain Ageing Education Program for Chronic Lung Disease Is Feasible in Rural Areas, Technological Challenges Notwithstanding - Pilot Randomized Controlled Trial/ R. Disler, Melbourne, Australia 421 Developing and Evaluating the Living Better @home With COVID-19 Model: A Co-designed Home-based Management Model for People From Arabic-speaking Communities/ C.Y. Tang, Penrith, Australia 422 Requirements for Home Oxygen After Hospitalization for COVID-19 in 2020 and 2021: Results From the U.S. Oxford Multicenter Retrospective Cohort Study/ M.B. Freedman, Chicago, IL 423 Patient Subgroups Most Likely to Benefit From Shorter Time-to-antibiotics in Sepsis/ R.K. Hechtman, Ann Arbor, MI 424 Physician and Patient Perspectives on Treatment Adherence in Asthma Management: Results From Apparent 1&2/ G. Walter Canonica, Milan, Italy

Bed Allocation Priority Using Intraclass Correlation Coefficients (ICC)/ I.O. Emeruwa, Los Angeles, CA

CLINICAL POSTER DISCUSSION SESSION

D23

DIAGNOSTIC DILEMMAS: CASE REPORTS IN INTERSTITIAL LUNG DISEASE AND LUNG TRANSPLANTATION

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Room 209 A-C (Level 2)

Poster Viewing

8:00-8:45 8:45-10:00

Discussion

Chairing: N. Gupta, MD, Cincinnati, OH A.L. Gray, MD, Aurora, CO

J.R. Miedema, MD, Rotterdam, Netherlands 801 An Unusual Case of Blue Finger Syndrome and Interstitial Lung Disease Secondary Anti-PL7 Antibody Positive Antisynthetase Syndrome/ D. Gil-Calderon, Bogota, Colombia 802 An Unusual Case Presentation of Clinically Amyopathic Dermatomyositis in a 63 Year Old Male/ M. Dasgupta, Chicago, IL 803 RP ILD and Anti MDA5 Antibody Dermatomyositis, A Case Series/ S. Chakravorty, Falls Church, VA 804 Prolonged Extracorporeal Membrane Oxygenation as a Bridge to a Successful Transplant in a Patient With Rapidly Progressive Interstitial Lung Disease/ J.M. Chowdhury, Falls Church, VA 805 Acute Hypoxic Respiratory Failure in Setting of Bronchiolitis Obliterans After COVID-19 Infection Complicated by Pulmonary Hypertension/ M.F. Hajmurad, Greenville, SC 806 The Use Of Human Immunoglobulin In The Treatment Of Covid-19 Pneumonia In Hematologic Patients: A Single-center Case Series/ P.M. Leone, Rome, Italy 807 Progressive Fibrosis in Pre-existing Interstitial Lung Disease Following COVID-19 Infection/ M.P. Mohning, Denver, CO 808 Robotic Lung Transplantation/ J. Thomas, Los Angeles, CA 809 Lung Transplantation Following a Heart Transplantation/ J.Y. You, Cleveland, OH

ATS 2023 • Washington, DC